The plausibility battleground at the EPO

The European Patent Office (EPO), as the central organ of the European patent system, rewards inventors or their legal successors for their technical contribution to art with patent monopolies, fostering and stimulating innovation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Is there a step between ‘inventive’ and ‘nonobviousness’?

12 September 2023 Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.

Biotechnology

A stricter interpretation: the EPO and antibodies

27 October 2020 Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.

Americas

3 July 2015 The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.

More on this story

Big Pharma

Is there a step between ‘inventive’ and ‘nonobviousness’?

12 September 2023 Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.

Biotechnology

A stricter interpretation: the EPO and antibodies

Americas

3 July 2015 The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.

More on this story

Big Pharma

Is there a step between ‘inventive’ and ‘nonobviousness’?

12 September 2023 Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.

Biotechnology

A stricter interpretation: the EPO and antibodies

Americas

3 July 2015 The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.

More features

'Nothing can stand in the way of our work': Ukraine resumes IP system

Life sciences leaders recognised at LSPN Awards USA 2025

ResMed voids sleep apnoea tech patent at PTAB

UPC orders 17-country ban on EOFlow's pumps in Insulet feud

US warns of rising counterfeit drug threat from India and China

Biotech and healthcare expert returns to Latham & Watkins

AstraZeneca to appeal invalidated diabetes patent in generics dispute

Commercialising genomic tech in Nigeria

The plausibility battleground at the EPO

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features